Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Phenylbutazone sodium
RN: 129-18-0
UNII: 189M850I32
InChIKey: VYOUHDLOIRJOSW-UHFFFAOYSA-N

Note

  • A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.

Molecular Formulas

  • C19-H19-N2-O2.Na
  • C19-H20-N2-O2.Na

Molecular Weight

  • 330.3611
 

Classification Codes

  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Phenylbutazone sodium

Synonyms

  • 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidin sodium
  • 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione sodium salt
  • Butazolidine sodium
  • Diphenyldioxobutylpyrazolidine-butazolidine-sodium
  • EINECS 204-935-7
  • GP26872
  • Phenylbutazone sodium
  • Phenylbutazone sodium salt
  • RTECS UU4844000
  • Sodium butazolidine
  • Sodium phenylbutazone
  • Sodium salt of phenylbutazone
  • UNII-189M850I32

Systematic Names

  • 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-, monosodium salt
  • 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione, sodium salt

Registry Numbers

CAS Registry Number

  • 129-18-0

FDA UNII

  • 189M850I32

System Generated Number

  • 0000129180

Molecular Formulas

Molecular Formulas

  • C19-H19-N2-O2.Na
  • C19-H20-N2-O2.Na

Molecular Formula Fragments

  • C19-H19-N2-O2
  • C19-H20-N2-O2
  • COMPONENT
  • Na

Structure Descriptors

InChI

1S/C19H19N2O2.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;/h4-13H,2-3,14H2,1H3;/q-1;+1

InChIKey

VYOUHDLOIRJOSW-UHFFFAOYSA-N

Smiles

CCCC[c-]1c(=O)n(n(c1=O)c2ccccc2)c3ccccc3.[Na+]

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 169mg/kg (169mg/kg)   Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970.
mouse LD50 intravenous 94mg/kg (94mg/kg)   Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958.
mouse LD50 oral 476mg/kg (476mg/kg)   Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970.
mouse LD50 subcutaneous 257mg/kg (257mg/kg)   Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 63, Pg. 43, 1967.
rabbit LD50 intravenous 146mg/kg (146mg/kg)   Schweizerische Medizinische Wochenschrift. Vol. 84, Pg. 1315, 1954.
rat LD50 intravenous 113mg/kg (113mg/kg)   Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958.
rat LD50 oral 855mg/kg (855mg/kg)   Indian Journal of Physiology and Pharmacology. Vol. 5, Pg. 113, 1961.
rat LD50 subcutaneous 310mg/kg (310mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 229, 1958.
women LDLo oral 16mg/kg/D (16mg/kg) LUNGS, THORAX, OR RESPIRATION: STRUCTURAL OR FUNCTIONAL CHANGE IN TRACHEA OR BRONCHI

BLOOD: AGRANULOCYTOSIS

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Annals of Internal Medicine. Vol. 39, Pg. 1096, 1953.